These trials completed more than 12 months ago and should have reported results.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
|Status||Trial ID||Title||Completion date||Category|
|Exempt, with results||2015-005609-34||Abrogation of chronic monoclonal antibody treatment-induced T-cell exhaustion with DURVALUMAB (MEDI4736) in advanced HER-2 negative breast cancer: a pilot proof-of-concept trial||not-yet-due|
|Ongoing||2017-002246-68||The DUTRENEO Trial: A Prospective Study to Individualize the Approach with DUrvalumab (MEDI4736) and TREmelimumab in NEOadjuvant Bladder Cancer patients.||not-yet-due|
|Exempt||2017-004367-12||A phase I-II study to evaluate the efficacy and safety of niraparib in combination with cabozantinib (XL184) in patients with advanced urothelial cancer after failure to first-line platinum-based chem...||not-yet-due|
|Ongoing||2017-004413-98||“Phase II clinical trial of doxycycline 50 mg or 100 mg daily for the prevention of skin toxicity in patients with metastatic colorectal cancer treated with panitumumab and chemotherapy"||not-yet-due|
|Ongoing||2018-003281-14||Multicenter, Open-Label, Single Arm, Phase II Exploratory Study to Evaluate the Reinduction and second stop of TKI with Ponatinib in CML in Molecular Response (ResToP)||not-yet-due|